Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer

Tagawa, Scott T.; Beltran, Himisha; Vallabhajosula, Shankar; Goldsmith, Stanley J.; Osborne, Joseph R.; Matulich, Dan; Petrillo, K.; Parmar, Sarojben; Nanus, David M.; Bander, Neil H.

doi:10.1002/cncr.24795

Cited by 122 publications

(89 citation statements)

References 62 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[37][38][39][40][41] Given the strong association of PSMA expression with survival it remains to be shown if a PSMA-specific targeting approach would show a therapeutic benefit in a subset of patients with oral squamous cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

et al. 2012

View full text Add to dashboard Cite

Prostate-specific membrane antigen (PSMA) is a transmembrane protein expressed in prostate cancer as well as in the neo-vasculature of nonprostatic solid tumors. Here, we determined the expression pattern of PSMA in the vasculature of oral squamous cell carcinoma. Using a previously validated antibody, PSMA staining distribution and cyclooxygenase 2 (COX2) expression status was evaluated in a cohort of patients with squamous cell carcinoma of the oral cavity (n ¼ 96) using immunohistochemistry and was correlated with clinicopathological features as well as outcome. Twenty-four (25%) cases showed no detectable PSMA staining, 48 (50%) demonstrated positive immunoreactivity for PSMA in less than 50% of microvessels and 24 (25%) cases showed strong endothelial PSMA expression in more than 50% of tumor-associated microvessels. High endothelial PSMA expression was associated with greatly reduced survival (18.2 vs 77.3 months; P ¼ 0.0001) and maintained prognostic significance after adjusting for grade and stage in multivariate analysis (hazard ratio ¼ 2.19, P ¼ 0.007). Furthermore, we observed a strong association between endothelial PSMA and cancer cell-specific COX2 expression. In conclusion, we provide the first evidence for the prognostic significance of endothelial PSMA expression in oral squamous cell carcinoma and, suggest a potential interaction between arachidonic acid metabolites and endothelial PSMA expression in the tumor neo-vasculature.

show abstract

Section: Discussionmentioning

confidence: 99%

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

et al. 2012

View full text Add to dashboard Cite

show abstract

“…A similar small molecule PSMA peptide ending with a different chemical conjugation ( 177 Lu PSMA‐I&T) also appears effective as a therapeutic agent in a number of published studies 3, 2118, 23 …”

Section: Labelling Of Lu 177 With Psma Peptides: Different Available mentioning

confidence: 99%

Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Emmett

Willowson

Violet

et al. 2017

J of Medical Radiation Sci

243

233

View full text Add to dashboard Cite

Prostate‐specific membrane antigen (PSMA) is a receptor on the surface of prostate cancer cells that is revolutionising the way we image and treat men with prostate cancer. New small molecule peptides with high‐binding affinity for the PSMA receptor have allowed high quality, highly specific PET imaging, in addition to the development of targeted radionuclide therapy for men with prostate cancer. This targeted therapy for prostate cancer has, to date, predominately used Lutetium 177 (Lu) labelled PSMA peptides. Early clinical studies evaluating the safety and efficacy of Lu PSMA therapy have demonstrated promising results with a significant proportion of men with metastatic prostate cancer, who have already failed other therapies, responding clinically to Lu PSMA. This review discusses the practical issues of administering Lu PSMA, and gives an overview of the findings from currently published trials in regards to treatment response rates, expected toxicities and safety.

show abstract

“…Radioimmunotherapy (RIT) with the use of radiolabeled monoclonal antibodies in PC patients has been reported with the 177 Lu-labeled anti-PSMA antibody J591. 1,2 However, due to the long circulatory half-life of agents based on intact antibody molecules, clinically relevant myelotoxicity limits the activity dose that can be safely administered. To avoid toxicity related to slow clearance of radiolabeled antibodies from the circulation, a pretargeting approach can be applied.…”

Section: Introductionmentioning

confidence: 99%

Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a ¹⁷⁷Lu-Labeled Peptide

RijCatharina

FrielinkCathelijne²,

GoldenbergDavid³

et al. 2014

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

TROP-2 is a pancarcinoma marker that is expressed at high levels in many epithelial cancers, including prostate cancer (PC). The trivalent bispecific antibody TF12 (anti-TROP2 · anti-HSG [histamine-succinyl-glycine]) has shown to effectively target PC. In this study, the efficacy of pretargeted radioimmunotherapy (PRIT) with multiple cycles of TF12 and Lu-hRS7 survived at the end of the experiment (150 days), compared with 80% in the mice that were treated with three cycles of PRIT and 70% in the group that received two cycles of PRIT. Clinically significant hematologic toxicity was found only in the groups that received either three cycles of PRIT ( p < 0.0009) or RIT ( p < 0.0001). Conclusions: TROP-2-expressing PC can be targeted efficiently with TF12 and radiolabeled IMP288. 177Lu-IMP288 accumulated rapidly in the tumors. PRIT of multiple cycles inhibited the growth of s.c. PC3 tumors. Clinically relevant hematological toxicity was observed in the group that received three cycles of PRIT; however, conventional RIT with the parent mAb 177 Lu-hRS7 was at least as effective with similar toxicity.

show abstract

Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer

Cited by 122 publications

References 62 publications

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a ¹⁷⁷Lu-Labeled Peptide

Contact Info

Product

Resources

About

Anti–prostate‐Specific membrane antigen‐based radioimmunotherapy for prostate cancer

Cited by 122 publications

References 62 publications

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity

Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a 177Lu-Labeled Peptide

Contact Info

Product

Resources

About

Lutetium ¹⁷⁷ PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy

Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a ¹⁷⁷Lu-Labeled Peptide